About the Company
We do not have any company description for REGENXBIO Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on REGENXBIO Inc.
US FDA extends review timeline of Regenxbio’s BLA for clemidsogene lanparvovec to treat Mucopolysaccharidosis II
US FDA extends review timeline of Regenxbio’s BLA for clemidsogene lanparvovec to treat Mucopolysaccharidosis II: Rockville, Maryland Wednesday, August 20, 2025, 18:00 Hrs [IST] ...
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) extended its review timeline of the Biologics License Application (BLA) for clemidsogene lanparvovec (RGX ...
REGENXBIO Inc.: REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
RGX-121 would be the first and only potential one-time commercially-available therapy designed to directly address the underlying genetic cause of Hunter syndrome ...
Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings
Regenxbio Inc (NASDAQ:RGNX) is set to release its Q3 2024 earnings on Nov 6, 2024. The consensus estimate for Q3 2024 revenue is $23.59 million, and the earnings are expected to come in at -$1.12 ...
Are Options Traders Betting on a Big Move in Regenxbio Stock?
Investors in REGENXBIO Inc. RGNX need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 17, 2025 $5.00 Call had some of the highest implied ...
REGENXBIO Announces Completion of Dosing in the Phase I/II ... - Nasdaq
--REGENXBIO Inc. today announced it has completed dosing in the expanded Cohort 2 of the Phase I/II trial of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I. The trial has now ...
RegenXbio's Potential Blockbuster: Analyst is Bullish On ... - Benzinga
Baird has initiated coverage on RegenXbio Inc RGNX with an Outperform rating and a price target of $42. The analyst writes that Regenx has one of the most broad approaches to AAV-based gene therapies.
RGNX | REGENXBIO Inc. Annual Income Statement | MarketWatch
REGENXBIO Inc. Annual stock financials by MarketWatch. View the latest RGNX financial statements, income statements and financial ratios.
Rockville’s RegenxBio expands roles of 2 C-suite executives ...
She came to RegenxBio from Gaithersburg’s Novavax Inc., where she was head of talent management, and had previously worked for the Howard Hughes Medical Institute and Human Genome Sciences.
REGENXBIO Inc. (RGNX) Q1 2023 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2023 Results Conference Call May 3, 2023 4:30 PM ETCompany ParticipantsPatrick Christmas - EVP and Chief Legal OfficerKen ...
REGENXBIO Inc. (RGNX) Q2 2023 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ: RGNX) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - Chief Executive Officer Steve ...
REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript
REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.41, expectations were $-1.44. Operator: Good day, and thank you for standing by. Welcome to REGENXBIO’s Third Quarter 2023 ...
Similar Companies
Loading the latest forecasts...